RxDoctor Payments Data

Moses Muzquiz, MD

Family Medicine · Palatka, FLNPI 1043223753

Payments from drug & device makers

$2,793in general payments, 2019–2025

Across 112 payments — averaging $24.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$933
  • Novo Nordisk$530
  • Amgen$284
  • Lilly USA, LLC$260
  • Pfizer$219
  • Abbott$118
  • plus $450 from 11 others

What the payments were for

  • Food & beverage$2,74998%
  • Education$442%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,793 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$92,967
Medicare patients
312
Services billed
1,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$81,342
JanuviaSitagliptin Phosphate59$45,353
MounjaroTirzepatide36$40,707
EliquisApixaban30$29,908
XareltoRivaroxaban31$23,450
MyrbetriqMirabegron19$13,516
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$12,964
FarxigaDapagliflozin Propanediol11$10,438
PremarinEstrogens, Conjugated12$5,051
Atorvastatin Calcium407$3,769
Estradiol21$3,034
SymbicortBudesonide/Formoterol Fumarate12$3,015
Levothyroxine Sodium214$2,689
Rosuvastatin Calcium188$2,365
Sildenafil Citrate27$2,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$530$81,34284 claims
MerckJanuvia$33$45,35359 claims
Lilly USA, LLCMounjaro, Olanzapine$260$41,75354 claims
PfizerEliquis, Premarin$219$34,95942 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$933$26,41742 claims
Astellas Pharma US IncMyrbetriq$70$13,51619 claims
AbbVieSynthroid$14$2,10425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Palatka

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →